Suzuki Motor resumes manufacturing operations at Gujarat plant; says will adhere to govt regulations, norms

Suzuki Motor had suspended production at the Hansalpur (Gujarat) plant on 23 March to check the spread of COVID-19.

Press Trust of India May 25, 2020 11:58:17 IST
Suzuki Motor resumes manufacturing operations at Gujarat plant; says will adhere to govt regulations, norms

New Delhi: Maruti Suzuki India (MSI) on Monday said Suzuki Motor Gujarat has resumed manufacturing operations after having suspended work for over two months due to coronavirus lockdown.

Suzuki Motor Gujarat (SMG) manufactures cars on a contract basis for MSI.

Suzuki Motor resumes manufacturing operations at Gujarat plant says will adhere to govt regulations norms

Representational image. Reuters.

The company has been informed by SMG that it would re-start production of vehicles from the 25 May, strictly in accordance with the government regulations and guidelines, MSI said in a regulatory filing.

SMG had suspended production at the Hansalpur (Gujarat) plant on 23 March to check the spread of COVID-19.

The facility, which rolls out two models, Baleno and Swift, currently has an installed production capacity of 5 lakh units per annum.

MSI has already commenced operations at its two plants in Manesar and Gurugram.

Both the plants have an installed capacity to produce over 15.5 lakh units per annum.

The Gurugram facility rolls out models like S-Cross, Vitara Brezza, Ignis and Super Carry light commercial vehicle.

The Manesar plant, on the other hand, produces high selling models like Alto, Swift, Dzire, S-Presso, Ertiga and Baleno.

Updated Date:

also read

Investing in fever screening will not help curb the spread of COVID-19, say experts
science

Investing in fever screening will not help curb the spread of COVID-19, say experts

Not only is fever screening unreliable, infrared thermometry puts the device's operator at risk. It also gives people who pass the test a false sense of security.

COVID-19 RECOVERY trial: HIV medicine found ineffective in treating hospitalised COVID-19 patients
World

COVID-19 RECOVERY trial: HIV medicine found ineffective in treating hospitalised COVID-19 patients

The HIV combination treatment lopinavir-ritonavir is also being studied in a trial by the World Health Organization.

'Protection is must': Experts urge public to strictly follow COVID-19 guidelines as India reports over 5 lakh cases
India

'Protection is must': Experts urge public to strictly follow COVID-19 guidelines as India reports over 5 lakh cases

Medical experts told ANI that the rise in cases in India is still not high as compared to other countries but said that people should follow COVID-19 guidelines such as wearing face masks. Dr Suresh Kumar, Medical Director, Lok Nayak Jai Prakash (LNJP) Hospital said that urban mobility is a likely cause in the spike in cases.